On June 1, 2022 Genomic Testing Cooperative, LCA (GTC) reported that it will be presenting at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) 2022 annual meeting data showcasing its new innovative approach to liquid biopsy testing that combines both cell-free-DNA (cfDNA) with cell-free RNA (cfRNA), Liquid Trace (Press release, Genomic Testing Cooperative, JUN 1, 2022, View Source [SID1234615349]). Liquid Trace tests both cfDNA and cfRNA not only improves sensitivity of the liquid biopsy but also provides transcriptome data that is enriched by various tumor markers (CA125, CA 15-3, CEA, etc) and makes it possible to perform liquid immunoprofiling by evaluating levels of CD19, CD20, CD33, CD4, CD8, etc.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
This data will be presented in two posters:
– "Combining cell-free RNA (cfRNA) with cell-free total nucleic acid (cfTNA) as a new paradigm for liquid biopsy." Abstract # 3048; Poster # 40, Sunday, June 5, 2022, 8:00 AM-11:00 AM CDT
– "Cell-free RNA in liquid biopsy and biomarkers profiling of hematologic and solid tumors."
Abstract # 3047, Poster # 39, Sunday, June 5, 2022, 8:00 AM-11:00 AM CDT
GTC will also present validation data of its innovative artificial Intelligence (AI) approach that uses targeted transcriptome to classify and aid in the differential diagnosis between 47 different diagnoses of hematologic and solid tumors. This AI is particularly powerful in the differential diagnosis between various types of lymphoma and Hodgkin disease and solid tumors of unknown origin. This data will be presented in the following poster:
– "Differential diagnosis of hematologic and solid tumors using targeted transcriptome and artificial intelligence." Abstract # 3018; Poster # 10; Sunday, June 5, 2022, 8:00 AM-11:00 AM CDT; 4:30 PM-6:00 PM (Discussion)
"Our new Liquid Trace test represents a significant leap in the science of liquid biopsy. Cells in various tissues contain the same DNA, but RNA makes the difference between skin and brain tissue. Analyzing RNA is the next step in the advancement of genomics. GTC is committed to combining the science of RNA with AI to bring this type of innovation to everyday practice of molecular testing in tissue biopsy as well as in liquid biopsy," stated Dr. Maher Albitar, founder, chief medical officer, and chief executive officer of GTC. "These advances were possible because of the collaborative (Co-Op) business model that was adapted by GTC. Collaboration between various Co-Op members accelerates innovation and advances genomics. We are grateful for the support and collaborative efforts of various members of the Co-Op"
Visit GTC at booth #4117 at ASCO (Free ASCO Whitepaper) for more details and highlights on this work and on how to become a member of the Co-Op. The abstracts presented at ASCO (Free ASCO Whitepaper) will be made available on GTC’s website after the ASCO (Free ASCO Whitepaper) meeting.